This review explores the topic of microRNAs (miRNAs) for improved early detection of imperceptible cancers, with potential to advance precision medicine and improve patient outcomes. Historical research exploring miRNA's role in cancer detection collectively revealed initial hurdles in identifying specific miRNA signatures for early-stage and difficult-to-detect cancers. Early studies faced challenges in establishing robust biomarker panels and overcoming the heterogeneity of cancer types. Despite this, recent developments have supported the potential of miRNAs as sensitive and specific biomarkers for early cancer detection as well as having demonstrated remarkable potential as diagnostic tools for imperceptible cancers, such as those with elusive symptoms or challenging diagnostic criteria. This review discusses the advent of high-throughput technologies that have enabled comprehensive detection and profiling of unique miRNA signatures associated with early-stage cancers. Furthermore, advancements in bioinformatics and machine-learning techniques are considered, exploring the integration of multi-omics data which have potential to enhance both the accuracy and reliability of miRNA-based cancer detection assays. Finally, perspectives on the continuing development on technologies as well as discussion around challenges that remain, such as the need for standardised protocols and addressing the complex interplay of miRNAs in cancer biology are conferred.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11226400 | PMC |
| http://dx.doi.org/10.1038/s41388-024-03076-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK inhibitors.
Theranostics
January 2025
College of Pharmacy, Research Institute of Pharmaceutical Sciences and Natural Products Research Institute, Seoul National University, Seoul 08826, Republic of Korea.
Radiotherapy is a widely employed technique for eradication of tumor using high-energy beams, and has been applied to approximately 50% of all solid tumor patients. However, its non-specific, cell-killing property leads to inevitable damage to surrounding normal tissues. Recent findings suggest that radiotherapy-induced tissue damage contributes to the formation of a pro-tumorigenic microenvironment.
View Article and Find Full Text PDFAI-Driven insights in pancreatic cancer imaging: from pre-diagnostic detection to prognostication.
Abdom Radiol (NY)
December 2024
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States, largely due to its poor five-year survival rate and frequent late-stage diagnosis. A significant barrier to early detection even in high-risk cohorts is that the pancreas often appears morphologically normal during the pre-diagnostic phase. Yet, the disease can progress rapidly from subclinical stages to widespread metastasis, undermining the effectiveness of screening.
View Article and Find Full Text PDFInferior vena cava leiomyosarcoma mimicking an exophytic intrahepatic cholangiocarcinoma.
Intractable Rare Dis Res
November 2024
Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada.
Inferior vena cava (IVC) leiomyosarcomas are rare smooth muscle neoplasms that account for 0.5% of adult soft tissue sarcomas. They present with nonspecific symptoms and have poor prognosis.
View Article and Find Full Text PDFApplications and Integration of Radiomics for Skull Base Oncology.
Adv Exp Med Biol
November 2024
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- Radiomics uses quantitative methods to analyze medical images, revealing hidden patterns that may serve as noninvasive biomarkers in skull base oncology.
- Applications mainly focus on three tumor types: meningioma, sellar/parasellar tumors, and vestibular schwannomas, with investigations covering areas like tumor detection, classification, grading, and prognosis.
- Despite advancements and the use of deep-learning methods, challenges such as small sample sizes and limited diversity in data hinder broader adoption, highlighting the need for multi-institutional collaboration to validate radiomic technologies.
Machine Learning and Radiomics in Gliomas.
Adv Exp Med Biol
November 2024
Department of Neurosurgery, Río Hortega University Hospital, Valladolid, Spain.
The integration of machine learning (ML) and radiomics is emerging as a pivotal advancement in glioma research, offering novel insights into the diagnosis, prognosis, and treatment of these complex tumors. Radiomics involves the extraction of a multitude of quantitative features from medical images. When these features are analyzed through ML algorithms, the precision of tumor characterization is enhanced beyond traditional methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!